Montreal, QC – Drug discovery company Chronogen has appointed Dr Max Fehlmann as its new president and chief executive officer and as a member of its board of directors.
The company develops human therapeutics to treat age-dependent diseases.
Dr Fehlmann has worked as a senior executive in both private and public bio-pharmaceutical organizations. He was president and CEO of Aster Biotechnologies, which grew from two to 35 employees and was eventually sold to multinational pharmaceutical company Zambon Group,at which time he became R&D director of the entire group. He holds a PhD from Laval University, a DSc from the University of Nice and a MBA from CPA-Mediterrannee in Sophia-Antipolis.